1 / 23

Presentation By: Anthony Soriano Hsiang-En Chou Xiao Pu Rafael Mora Ivy Yeung

Presentation By: Anthony Soriano Hsiang-En Chou Xiao Pu Rafael Mora Ivy Yeung. About Amgen. Established company founded in Delaware in 1980. Employs over 17,800 people. One of the World's largest Biotech Companies. They market 5 of the world's best selling drugs. . Mission :

jud
Download Presentation

Presentation By: Anthony Soriano Hsiang-En Chou Xiao Pu Rafael Mora Ivy Yeung

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Presentation By: Anthony Soriano Hsiang-En Chou Xiao Pu Rafael Mora Ivy Yeung

  2. About Amgen • Established company founded in Delaware in 1980. • Employs over 17,800 people. • One of the World's largest Biotech Companies. • They market 5 of the world's best selling drugs.

  3. Mission: • To Serve Patients Values: • Compete Intensely and Win • Create Value for Patients, Staff and Stockholders • Be Ethical • Trust and Respect Each Other • Work in Teams

  4. Locations • Thousand Oaks,CA (Headquarter) • 12 branches in U.S. • 35 branches in Europe • 3 branches in Asia • 2 branches in Canada • 2 branches in Australia • 1 branches in Mexico • 1 branches in South America

  5. Leadership • EVP, Operations • Since 1997, held roles as vice president, Information Management, and director, Engineering Operations Services MadhavanBalachandran Robert A. Bradway • Chairman and CEO • EVP and chief financial officer 2007 – 2010 • President and chief operating officer current Jonathan M. Peacock • EVP and CFO • Joined Amgen as chief financial officer in September 2010

  6. Products • Aranesp • Aranesp is used to treat anemia (a lack of red blood cells in the body). • Enbrel • Enbrel is used to treat the symptoms of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, and to prevent joint damage caused by these conditions. • EPOGEN • Epogen is used to treat anemia (a lack of red blood cells in the body) in patients with chronic kidney disease. • Video

  7. Subsidiaries • 1994 - Synergen, Inc. • 2000 - KinetixPharmaceuticals, Inc. • 2002 - ImmunexCorporation • 2004 - Tularik, Inc. • 2006 - Abgenix, Inc. • 2006 - Avidia, Inc. • 2007 - Ilypsa, Inc. • 2007 - AlantosPharmaceuticals Holdings, Inc. • 2011 - BioVexGroup, Inc. • 2011 - Laboratório Químico Farmacêutico Bergamo Ltda. • 2012 - Micromet, Inc. • 2012 - Mustafa Nevzatİlaç • 2012 - KAI Pharmaceuticals • 2012 - deCodeGenetics

  8. Accomplishment rankings • With $15,582 Million in Revenues, almost double the revenues of Gilead • S&P: A+ therefore we don't default on our debt and we are low-risk

  9. Amgen Inc: Today’s Featured Drugs Winner

  10. Stock price development

  11. Market ratios • Increasing P/E Ratio means the public is realizing the value of this stock.

  12. Liquidity Ratios • Excellent short term liquidity • Higher than most companies

  13. Activity Ratios • Biotech companies naturally have longer period to sell drug.

  14. Solvency Ratios • Company is taking out more debt to finance expansion • Plan to enter emerging markets across the world

  15. Profitability Ratios • Low operation costs for producing pill created huge gross profit margin. • Revenue much higher than COGS

  16. Future Development Longer-term growth may also be achieved by: • Expansion into emerging markets including Japan • Acquisition of BioVex, Bergamo and Micromet • Successful development of the later stage pipeline • Focus on increasing cost efficiencies • Significant savings after expiration of the ENBREL co-promotion agreement with Pfizer in the fourth quarter of 2013

  17. Future Challenges • Increasing competitive pressure, due to biosimilars • Expiration of patents in the coming years • Regulatory and reimbursement challenges • Macroeconomic conditions

  18. Mergers and Acquisitions • June 2012, acquired Turkish Pharmaceutical company MustadaNevzat • Acquired Immunuxmainly for its popular drug Enbrel which in 2011 generated $3.7 billion in revenue • Patent extended to 2028 • Signed long-term supply deal with leading dialysis provider DaVita in 2011 • In, 2012, Warrant Buffet invested 1.2 billion in DaVita

  19. SWOT Analysis • Strengths: Barriers to entry & Inelastic Demand • Weaknesses: FDA Approval • Opportunities: Emerging Markets • Threats: Failure to realize benefits

  20. Equity Incentive Plan • Provide Bonus Opportunities • Recently, company issued over 357 million stock-options • Life insurance equal to twice your base pay • 401K Retirement Plan

  21. Health and Benefits • Competitive health insurance • On-Site fitness center as well as healthy living classes. • Vacation time of at least 17 PAID holidays annually • Tuition reimbursement

  22. Thank You For Your Attention !

More Related